Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Dollar Tree, Inc. (DLTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Dollar Tree, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.81 (market cap $4.49B), while Dollar Tree, Inc. trades at $123.21 (market cap $23.57B). The key difference: Dollar Tree, Inc. is far larger — about 5.2× ACADIA Pharmaceuticals Inc.'s market cap. Which is the better fit depends on your goals.
| ACAD | DLTR | |
|---|---|---|
Market Cap | $4.49B | $23.57B |
Sector | Health | Health |
52-Week High | $28.06 | $141.21 |
52-Week Low | $20.06 | $85.04 |
Enterprise Value | $3.69B | $30.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Dollar Tree (DLTR) trades at $122.65, down 1.13% on the day, but maintains a bullish technical signal with strong moving average support. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Recent news highlights a new $2.5 billion share repurchase authorization, signaling management confidence. Revenue for 2025 was $17.58 billion, though net income was impacted by a significant tax expense, resulting in a loss. Analyst consensus is bullish with a $130.70 price target, and institutional sentiment is positive amid evolving value retail strategies.
The outlook for DLTR is cautiously optimistic, driven by earnings momentum, share buybacks, and margin improvements. Key opportunities include multi-price strategy gains and cost controls, but risks involve traffic softness, inflationary pressures, and competitive threats. The stock's current valuation metrics, such as a P/E of 19.5, appear reasonable relative to growth prospects, though investors should monitor execution against macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →
